TMDX
TransMedics Group, Inc.
$68.94
+0.09
(+0.12%)
Mkt Cap
2.38B
Volume
1,150,774
52W Range
60.105-156
Sector
Healthcare
Beta
2.06
EPS (TTM)
5.03
P/E Ratio
13.70
Revenue (TTM)
635.89M
Rev Growth (5Y)
+88.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$121.44
Undervalued · Strong
43.2% below fair value
AlphaQuality · Grade · Gated
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
Company Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.49M | 441.54M | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.68M | 6.21M |
| Net Income | 190.29M | 35.46M | (25.03M) | (36.23M) | (44.22M) | (28.75M) | (33.55M) | (23.76M) | (20.82M) | (24.07M) |
| EPS | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Free Cash Flow | 133.59M | (80.94M) | (192.09M) | (57.72M) | (32.38M) | (30.72M) | (32.45M) | (26.40M) | (23.36M) | (25.59M) |
| FCF / Share | 3.93 | -2.44 | -5.91 | -1.95 | -1.17 | -1.24 | -2.28 | -1.37 | -1.61 | -1.77 |
| Operating CF | 192.84M | 48.80M | (13.03M) | (45.82M) | (28.86M) | (30.27M) | (32.29M) | (25.98M) | (23.10M) | (24.11M) |
| Total Assets | 1.07B | 804.08M | 706.05M | 277.15M | 134.89M | 152.03M | 105.30M | 42.16M | 37.00M | 58.10M |
| Total Debt | 469.69M | 518.29M | 515.95M | 67.56M | 43.80M | 34.66M | 34.15M | 33.67M | 8.65M | 8.41M |
| Cash & Equiv | 488.37M | 336.65M | 394.81M | 201.18M | 25.58M | 24.58M | 20.09M | 20.24M | 11.94M | 9.84M |
| Book Value | 473.10M | 228.60M | 137.20M | 187.38M | 67.85M | 103.89M | 54.65M | (4.83M) | (168.72M) | 38.79M |
| Return on Equity | 0.40 | 0.16 | -0.18 | -0.19 | -0.65 | -0.28 | -0.61 | N/A | N/A | -0.62 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.93M | 160.76M | 143.82M | 157.37M | 143.54M | 121.62M | 108.76M | 114.31M | 96.85M | 81.17M | 66.43M | 52.47M |
| Net Income | 7.32M | 105.38M | 24.32M | 34.91M | 25.68M | 6.86M | 4.22M | 12.19M | 12.20M | 4.03M | (25.42M) | (1.00M) |
| EPS | 0.21 | 3.08 | 0.71 | 1.03 | 0.76 | 0.20 | 0.13 | 0.37 | 0.37 | 0.12 | -0.78 | -0.03 |
| Free Cash Flow | (12.12M) | 19.00M | 61.95M | 82.53M | (29.89M) | 6.06M | (41.35M) | 1.96M | (47.61M) | (33.51M) | (114.59M) | (7.18M) |
| FCF / Share | -0.35 | 0.56 | 1.82 | 2.43 | -0.89 | 0.18 | -1.24 | 0.06 | -1.45 | -1.03 | -3.51 | -0.22 |
| Operating CF | 24.53M | 34.51M | 69.57M | 91.61M | (2.85M) | 19.66M | 6.86M | 25.72M | (3.44M) | 8.30M | (6.87M) | (5.80M) |
| Total Assets | 1.43B | 1.07B | 946.03M | 890.52M | 837.53M | 804.08M | 785.57M | 758.58M | 723.83M | 706.05M | 689.23M | 690.36M |
| Total Debt | 818.75M | 469.69M | 519.35M | 518.82M | 518.41M | 518.29M | 518.15M | 516.49M | 516.22M | 515.95M | 515.65M | 515.01M |
| Cash & Equiv | 461.74M | 488.37M | 466.17M | 400.57M | 310.14M | 336.65M | 330.09M | 362.75M | 350.22M | 394.81M | 427.11M | 582.21M |
| Book Value | 494.01M | 473.10M | 355.20M | 318.10M | 266.31M | 228.60M | 209.92M | 189.89M | 159.47M | 137.20M | 126.46M | 145.21M |
| Return on Equity | 0.01 | 0.22 | 0.07 | 0.11 | 0.10 | 0.03 | 0.02 | 0.06 | 0.08 | 0.03 | -0.20 | -0.01 |
TMDX News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
TransMedics: Cheaper, But Still Priced For Perfection
TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say
TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates
TransMedics Reports First Quarter 2026 Financial Results
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
TransMedics: Revolutionizing The Organ Transplant Market While Trading At A Discount